This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
PEACE-3 Trial
PROfound Trial
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
VISION Trial
mHSPC
ARANOTE Trial
ARASENS Trial
nmCRPC
ARAMIS Trial
nmCSPC
EMBARK Trial
PSMA PET Imaging
COBRA Trial
CONDOR Trial
OSPREY Trial
Bladder Cancer
ANKTIVA
Bladder Cancer Detection
CORE-001 Study
ADSTILADRIN
Centers of Excellence
Urologic Oncology
Left Group
Health Policy
Health Policy
Ruchika Talwar, MD
Bladder Cancer
Bladder Cancer
Ashish Kamat, MD
Advanced Bladder Cancer
Shilpa Gupta, MD
Trimodality Therapy
Leslie Ballas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Endourology
Endourology
Jaime Landman, MD
Prostate Cancer
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
Decipher Genomic Classifier
Imaging Center
Phillip Koo, MD
mHSPC
Neeraj Agarwal, FASCO, MD
nmCRPC
Zachary Klaassen, MD, MSc
mCRPC Treatment
A. Oliver Sartor, MD
PSMA-Targeted Therapy
Advanced Prostate Cancer
Zachary Klaassen, MD, MSc
Disparities: Social Determinants of Health
Disparities: Social Determinants of Health
Samuel L. Washington III, MD, MAS
Translational Prostate Cancer
Translational Science in Prostate Cancer
Andrea Miyahira, Ph.D
Women in Science
Andrea Miyahira, Ph.D
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
TESTICULAR, PENILE & RARE GU MALIGNANCIES
Testicular Cancer
Pelvic Health & Reconstruction
Bladder Health
Diane K. Newman, DNP, ANP-BC, FAAN
Pelvic Health
Diane K. Newman, DNP, ANP-BC, FAAN
Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
Stephen R. Kraus, MD
Urologic Catheters (Includes CAUTI)
Diane K. Newman, DNP, ANP-BC, FAAN
Videos
Exclusives
Conferences
Exclusive Collaborations
Independent Medical Education
Covid-19
The Prostate Cancer Foundation
Health Policy in Urological Diseases
Disparities: Social Determinants of Health
Practice Guidelines Reviews
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Testicular Cancer
Endourology
Pelvic Health & Reconstruction
Pelvic Health & Reconstruction
Trials in Progress
Trials in Progress
Bladder Cancer
IMMORTAL
PIVOT-006
Kidney Cancer
RadiCal
SAMURAI
Middle Side
Prostate Cancer
ARAMON
ARASEC
ARASTEP
CLARIFY
ECLIPSE
ESCAPE
FORT
Right Side
Prostate Cancer
Masofaniten (EPI-7386)
METANOVA
NRG-GU 0101
PROMISE
RTIRE
SECuRE
SHORTER
Clinical Trials
From the Editor
Search Clinical Trials
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
SCS AUA 2024
ASTRO 2024
IBCN 2024
ESMO 2024
BCAN TT 2024
All Conferences
View All
Quick Takes
ESMO 2024
PCF
UroToday Home
Conference Highlights
ASCO GU 2020
ASCO GU 2020
Prostate Cancer
Kidney Cancer
Bladder Cancer
Penile, Urethral, Testicular, and Adrenal Cancers
Press Releases
ASCO GU 2020 Kidney Cancer
Viewing 1-20 of 57 articles
ASCO GU 2020: Best of Journals: Renal Cell Carcinoma - The Surgeon’s Perspective
ASCO GU 2020: Best of Journals: Renal Cell Carcinoma - The Pathologists Perspective
ASCO GU 2020: Comparing Nivolumab versus Everolimus with >5 years of Follow-up in Patients with Advanced Renal Cell Carcinoma: A Final Analysis of the CheckMate 025 Trial
ASCO GU 2020: Challenging Clinical Scenarios in the Management of Renal Cell Carcinoma - From the Perspective of a Radiologist
ASCO GU 2020: The Prevalence and Landscape of Actionable Genomic Alterations in Renal Cell Carcinoma
ASCO GU 2020: A Phase I/II Study of Sitravatinib Combined with Nivolumab in Patients with Advanced Clear Cell Renal Cancer that Progressed on Prior Anti-Angiogenic Therapy
ASCO GU 2020: Overall Survival Results for Durvalumab and Savolitinib in Metastatic Papillary Renal Cancer — CALYPSO trial
ASCO GU 2020: Novel Drugs for Clear Cell Renal Cell Carcinoma
ASCO GU 2020: Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors or Targeted Therapy
ASCO GU 2020: Challenging Clinical Scenarios in the Management of Renal Cell Carcinoma: Genomic Findings
ASCO GU 2020: Evaluation of RNA-Sequencing Signatures with Pembrolizumab in Patients with Renal Cell Carcinoma from KEYNOTE-427 Cohort A
ASCO GU 2020: Challenging Clinical Scenarios in the Management of Renal Cell Carcinoma: Neoadjuvant Therapy for Localized RCC
ASCO GU 2020: Nonsurgical Local Treatment Options and Their Limits: Stereotactic Radiation
ASCO GU 2020: Nonsurgical Local Treatment Options and Their Limits: Percutaneous Ablation
ASCO GU 2020: Depth of Response (DepOR) Analysis and Correlation with Clinical Outcomes from JAVELIN Renal 101
ASCO GU 2020: Molecular Characteristics of Renal Cell Carcinoma Risk Groups from JAVELIN Renal 101
ASCO GU 2020: Evaluation of Brain Metastasis in JAVELIN Renal 101: Efficacy of Avelumab + Axitinib versus Sunitinib
ASCO GU 2020: (NIVOSWITCH) - Switch to Nivolumab with TKI Continuation After 12 Weeks of TKI Induction Therapy in Metastatic Renal Cell Carcinoma
ASCO GU 2020: Challenging Clinical Scenarios in the Management of Renal Cell Carcinoma: Rechallenge with ICI Following Immune-Related Adverse Events
ASCO GU 2020: Emerging therapies in Renal Cell Carcinoma: From PARP Inhibition to Novel Immunotherapy Agents
1
2
3
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free